Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
Age, marital status, and geographic location tended to influence use of oral anticancer therapy in older patients with metastatic RCC.